REN Stock Analysis: Relx | AS
Specialty Business Services | AS, Netherlands | Market Cap: 56.021m EUR | 12M Return: -13.8% | GB00B2B0DG97 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 23.1M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
RELX PLC is a UK-headquartered provider of information-based analytics and decision tools for professional and business customers across North America, Europe, and other international markets. The company operates through four segments: Risk (offering analytics that combine public and industry-specific content with proprietary technology to help clients evaluate and predict risk, along with commercial healthcare products); Scientific, Technical & Medical (providing scientific and medical information and data sets); Legal (delivering legal, regulatory, and business information and analytics); and Exhibitions (combining digital tools and data to support in-person and online events, lead generation, and transactions).
The company was incorporated in 1903 and was formerly known as Reed Elsevier PLC before adopting its current name in July 2015. RELX operates a subscription- and data-driven B2B business model, monetizing proprietary content, analytics, and platforms primarily through recurring contracts with professional users in industries such as insurance, healthcare, science, law, and events. It is classified within the Industrials sector under the Diversified Support Services sub-industry.
- Risk segment analytics drives organic revenue growth above peers
- Exhibitions recovery exposed to global event spending cycle
- Subscription pricing and buybacks expand operating margins and EPS
| Net Income: 2.26b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 3.50 > 1.0 |
| NWC/Revenue: -36.74% < 20% (prev -31.89%; Δ -4.85% < -1%) |
| CFO/TA 0.20 > 3% & CFO 2.92b > Net Income 2.26b |
| Net Debt (8.74b) to EBITDA (3.88b): 2.25 < 3 |
| Current Ratio: 0.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.79b) vs 12m ago -6.05% < -2% |
| Gross Margin: 62.64% > 18% (prev 65.48%; Δ -2.84% > 0.5%) |
| Asset Turnover: 66.24% > 50% (prev 66.55%; Δ -0.31% > 0%) |
| Interest Coverage Ratio: 16.67 > 6 (EBIT TTM 3.13b / Interest Expense TTM 187.5m) |
| DSRI: 1.06 (Receivables 2.33b/2.16b, Revenue 9.70b/9.53b) |
| GMI: 1.05 (GM 65.48% / 62.64%) |
| AQI: 0.99 (AQ_t 0.79 / AQ_t-1 0.80) |
| SGI: 1.02 (Revenue 9.70b / 9.53b) |
| TATA: -0.04 (NI 2.26b - CFO 2.92b) / TA 14.9b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of October 14, 2026, the stock is trading at EUR 32.88 with a total of 591,447 shares traded. Over the past week, the price has changed by +8.09%, over one month by +7.52%, over three months by +13.40% and over the past year by -13.81%.
Current recommended Stop Loss: 31.60 (which is 3.9% or 1.4 ATR below the current price).
Relx has no consensus analysts rating.
Market Cap GBP = 47.3b (56.0b EUR * 0.8446 EUR.GBP)
P/E Trailing = 22.3889
P/E Forward = 15.3846
P/S = 5.7635
P/B = 35.3274
P/EG = 1.1835
Revenue TTM = 9.70b GBP
EBIT TTM = 3.13b GBP
EBITDA TTM = 3.88b GBP
Long Term Debt = 5.63b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 2.33b GBP (from shortTermDebt, last quarter)
Debt = 8.95b GBP (from shortLongTermDebtTotal, last quarter) + Leases 97.0m
Net Debt = 8.74b GBP (calculated: Debt 8.95b - CCE 218.8m)
Enterprise Value = 56.1b GBP (47.3b + Debt 8.95b - CCE 218.8m)
Interest Coverage Ratio = 16.67 (Ebit TTM 3.13b / Interest Expense TTM 187.5m)
EV/FCF = 19.35x (Enterprise Value 56.1b / FCF TTM 2.90b)
FCF Yield = 5.17% (FCF TTM 2.90b / Enterprise Value 56.1b)
FCF Margin = 29.88% (FCF TTM 2.90b / Revenue TTM 9.70b)
Net Margin = 23.27% (Net Income TTM 2.26b / Revenue TTM 9.70b)
Gross Margin = 62.64% ((Revenue TTM 9.70b - Cost of Revenue TTM 3.62b) / Revenue TTM)
Gross Margin QoQ = 64.09% (prev 61.19%)
Tobins Q-Ratio = 3.75 (Enterprise Value 56.1b / Total Assets 14.9b)
Interest Expense / Debt = 2.09% (Interest Expense 187.5m / Debt 8.95b)
Taxrate = 23.95% (714.3m / 2.98b)
NOPAT = 2.38b (EBIT 3.13b * (1 - 23.95%))
Current Ratio = 0.45 (Total Current Assets 2.90b / Total Current Liabilities 6.46b)
Debt / Equity = 7.27 (Debt 8.95b / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = 2.25 (Net Debt 8.74b / EBITDA 3.88b)
Debt / FCF = 3.02 (Net Debt 8.74b / FCF TTM 2.90b)
Total Stockholder Equity = 2.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.41% (Net Income 2.26b / Total Assets 14.9b)
RoE = 97.47% (Net Income TTM 2.26b / Total Stockholder Equity 2.31b)
RoCE = 39.34% (EBIT 3.13b / Capital Employed (Equity 2.31b + L.T.Debt 5.63b))
RoIC = 22.42% (NOPAT 2.38b / Invested Capital 10.6b)
WACC = 4.95% (E(47.3b)/V(56.3b) * Re(5.58%) + D(8.95b)/V(56.3b) * Rd(2.09%) * (1-Tc(0.24)))
Discount Rate = 5.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.42 | Cagr: -3.43%
[DCF] Terminal Value 77.97% ; FCFF base≈2.65b ; Y1≈3.04b ; Y5≈4.47b
[DCF] Fair Price = 33.66 (EV 67.2b - Net Debt 8.74b = Equity 58.5b / Shares 1.74b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.98 | Revenue CAGR: 2.23% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.68 | Chg30d=-0.10% | Revisions=-25% | GrowthEPS=+14.4% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=1.90 | Chg30d=+0.04% | Revisions=-25% | GrowthEPS=+12.8% | GrowthRev=+6.6%
[Analyst] Revisions Ratio: -40% (up=0, down=2)